Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option

Core Viewpoint - Calidi Biotherapeutics, Inc. has successfully closed a public offering, raising approximately $6.0 million in gross proceeds, which will support its ongoing development of targeted genetic medicines [1][2]. Group 1: Offering Details - The company sold a total of 12,094,631 shares of common stock and associated warrants, including the full exercise of the underwriters' option for an additional 1,575,000 shares [2]. - The Series J, K, and L warrants each have an initial exercise price of $0.50 per share, with varying terms of five years, one year, and six months from issuance respectively [5]. Group 2: Company Overview - Calidi Biotherapeutics is focused on developing targeted therapies that deliver genetic medicines to specific disease sites, utilizing its proprietary Redtail platform [7]. - The lead candidate, CLD-401, is currently in IND-enabling studies and targets non-small cell lung cancer and other high unmet medical need tumor types [8].